Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-α production

被引：138

作者：

Clark, MP ^{[1
]}

Laughlin, SK ^{[1
]}

Laufersweiler, MJ ^{[1
]}

Bookland, RG ^{[1
]}

Brugel, TA ^{[1
]}

Golebiowski, A ^{[1
]}

Sabat, MP ^{[1
]}

Townes, JA ^{[1
]}

VanRens, JC ^{[1
]}

Djung, JF ^{[1
]}

Natchus, MG ^{[1
]}

De, B ^{[1
]}

Hsieh, LC ^{[1
]}

Xu, SC ^{[1
]}

Walter, RL ^{[1
]}

Mekel, MJ ^{[1
]}

Heitmeyer, SA ^{[1
]}

Brown, KK ^{[1
]}

Juergens, K ^{[1
]}

Taiwo, YO ^{[1
]}

Janusz, MJ ^{[1
]}

机构：

[1] Procter & Gamble Pharmaceut, Mason, OH 45040 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2004年 / 47卷 / 11期

关键词：

D O I：

10.1021/jm049968m

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

2-Aryl-3-pyrimidinyl based tumor necrosis factor-alpha (TNF-alpha) inhibitors, which contain a novel bicyclic pyrazolope core, are described. Many showed low-nanomolar activity against lipopolysaccharide-induced TNF-alpha production in monocytic cells. Secondary screening data are presented for the pyrimidinyl bicyclic pyrazolones. Several of these analogues showed good oral bioavailability in rat and efficacy in the rat iodoacetate in vivo model.

引用

页码：2724 / 2727

页数：4

共 50 条

[21] Discovery of an Orally Active Small-Molecule Tumor Necrosis Factor-α Inhibitor
Sun, Weiguang
Wu, Yanli
Zheng, Mengzhu
Yang, Yueying
Liu, Yang
Wu, Canrong
Zhou, Yirong
Zhang, Yonghui
Chen, Lixia
Li, Hua
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (15) : 8146 - 8156
[22] Design, synthesis and bioactivities of novel diarylthiophenes:: inhibitors of tumor necrosis factor-α (TNF-α) production
Fujita, M
Hirayama, T
Ikeda, N
BIOORGANIC & MEDICINAL CHEMISTRY, 2002, 10 (10) : 3113 - 3122
[23] Tumor necrosis factor-α and the development of multiple organ failure
Moldawer, LL
Minter, RM
CRITICAL CARE MEDICINE, 2000, 28 (06) : 2158 - 2159
[24] Natural inhibitors of tumour necrosis factor-α production, secretion and function
Habtemariam, S
PLANTA MEDICA, 2000, 66 (04) : 303 - 313
[25] Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors
Zbinden, KG
Obst-Sander, U
Hilpert, K
Kühne, H
Banner, DW
Böhm, HJ
Stahl, M
Ackermann, J
Alig, L
Weber, L
Wessel, HP
Riederer, MA
Tschopp, TB
Lavé, T
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (23) : 5344 - 5352
[26] Tumor necrosis factor-α-converting enzyme and tumor necrosis factor-α in human dilated cardiomyopathy
Satoh, M
Nakamura, M
Saitoh, H
Satoh, H
Maesawa, C
Segawa, N
Tashiro, A
Hiramori, K
CIRCULATION, 1999, 99 (25) : 3260 - 3265
[27] The gene polymorphism of tumor necrosis factor-β, but not that of tumor necrosis factor-α, is associated with the prognosis of sarcoidosis
Yamaguchi, E
Itoh, A
Hizawa, N
Kawakami, Y
CHEST, 2001, 119 (03) : 753 - 761
[28] Cardiodepression by tumor necrosis factor-α
Müller-Werdan, U
Engelmann, H
Werdan, K
EUROPEAN CYTOKINE NETWORK, 1998, 9 (04) : 689 - 691
[29] Tumor necrosis factor-α and cardiomyopathy
Bristow, MR
CIRCULATION, 1998, 97 (14) : 1340 - 1341
[30] Thalidomide as an inhibitor of tumor necrosis factor-α production:: a word of caution
Pizarro, A
García-Tobaruela, A
Herranz, P
Pinilla, J
INTERNATIONAL JOURNAL OF DERMATOLOGY, 1999, 38 (01) : 76 - 77

← 1 2 3 4 5 →